Dar Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing women's health products in the United States. The company is headquartered in San Diego, California.
| Revenue (TTM) | $1.37M |
| Gross Profit (TTM) | 507,930 |
| EBITDA | $-8.98M |
| Operating Margin | -1583.00% |
| Return on Equity | -2543.00% |
| Return on Assets | -39.30% |
| Revenue/Share (TTM) | $0.10 |
| Book Value | $-0.04 |
| Price-to-Book | 29.40 |
| Price-to-Sales (TTM) | 10.20 |
| EV/Revenue | 1.378 |
| EV/EBITDA | -2.06 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 499.60% |
| Shares Outstanding | $14.98M |
| Float | $14.02M |
| % Insiders | 8.38% |
| % Institutions | 10.04% |
Volatility is currently expanding
National recognition comes as Daré Bioscience advances a multi-product women's health strategy across commercialization, clinical development and first-in-category innovation National recognition comes as Daré Bioscience advances a multi-product women's health strategy across commercialization, clinical development and first-in-category innovation
SAN DIEGO, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (Nasdaq: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that it has entered into a definitive securities purchase agreement with institutional investors for the purchase and sale of 4,379,581 shares of the Company's common stock (or pre-funded warrants to purchase shares of common stock in lieu thereof), at a price of $1.37 per share of common stock (or $1.3699 per pre-funded warrant) in a registered direct offering priced at-the-market under Nasdaq rules. Each pre-funded warrant will be exercisable upon issuance at an exercise price of $0.0001 per share and will expire when exercised in full.
Daré Bioscience, Inc. (DARE) Q2 2026 Earnings Call Transcript
Company launches Flora Sync LF5™, the company's first directly commercialized product, began generating revenue in July
SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that it will host a corporate update conference call and webcast at 4:30 PM Eastern Time on Thursday, August 13, 2026, to review its financial results for the quarter ended June 30, 2026 and to provide a company update.
Daré Bioscience, Inc. (DARE) Discusses Women's Health Portfolio and Commercialization Highlights on Virtual Bus Tour Transcript
A featured menopause telehealth option is now available to women exploring DARE to PLAY™, advancing Daré's strategy to build a trusted women's health ecosystem spanning products, education and access to care
SAN DIEGO, July 20, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced the launch of its "Across the U.S." Virtual Bus Tour Webinar Series, a multi-event investor engagement initiative designed to provide shareholders with direct access to the Company's leadership and the opportunity to learn more about Daré's commercial strategy, product portfolio, growth opportunities and long-term vision. Hosted by President and Chief Executive Officer, Sabrina Martucci Johnson, the live webinar series will feature corporate presentations, discussions surrounding the Company's women's health portfolio and commercialization strategy, updates on key business initiatives, and interactive question-and-answer sessions with investors.
Live video webcast on Tuesday, July 14 th , at 4:00 PM ET Register here
Commercial Launch Begins Company's First Consumer Revenue Stream, Bringing Science-Backed Women's Health Solutions Directly to Consumers Commercial Launch Begins Company's First Consumer Revenue Stream, Bringing Science-Backed Women's Health Solutions Directly to Consumers
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on DARE and any ticker you trade — then tracks every position and per-strategy win rate.
